A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors
This phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with exemestane or paclitaxel in patients with advanced solid tumors. This 3+3 dose-escalation study assessed BI 860585 monotherapy (5–300 mg/day;...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/6/1425 |
_version_ | 1797566479993929728 |
---|---|
author | Filippo de Braud Jean-Pascal H. Machiels Daniela Boggiani Sylvie W.H. Rottey Matteo Duca Marie Laruelle Stefania Salvagni Silvia Damian Lore D.F. Lapeire Marcello Tiseo Alexandre Dermine Mahmoud Ould-Kaci Juergen Braunger Juliane Rascher Daniela Fischer Josef Hoefler Gabriella L. Mariani Sara Cresta |
author_facet | Filippo de Braud Jean-Pascal H. Machiels Daniela Boggiani Sylvie W.H. Rottey Matteo Duca Marie Laruelle Stefania Salvagni Silvia Damian Lore D.F. Lapeire Marcello Tiseo Alexandre Dermine Mahmoud Ould-Kaci Juergen Braunger Juliane Rascher Daniela Fischer Josef Hoefler Gabriella L. Mariani Sara Cresta |
author_sort | Filippo de Braud |
collection | DOAJ |
description | This phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with exemestane or paclitaxel in patients with advanced solid tumors. This 3+3 dose-escalation study assessed BI 860585 monotherapy (5–300 mg/day; Arm A), BI 860585 (40–220 mg/day; Arm B) with 25 mg/day exemestane, and BI 860585 (80–220 mg/day; Arm C) with 60–80 mg/m<sup>2</sup>/week paclitaxel, in 28-day cycles. Primary endpoints were the number of patients with dose-limiting toxicities (DLTs) in cycle 1 and the MTD. Forty-one, 25, and 24 patients were treated (Arms A, B, and C). DLTs were observed in four (rash (<i>n</i> = 2), elevated alanine aminotransferase/aspartate aminotransferase, diarrhea), four (rash (<i>n</i> = 3), stomatitis, and increased gamma-glutamyl transferase), and two (diarrhea, increased blood creatine phosphokinase) patients in cycle 1. The BI 860585 MTD was 220 mg/day (Arm A) and 160 mg/day (Arms B and C). Nine patients achieved an objective response (Arm B: Four partial responses (PRs); Arm C: Four PRs; one complete response). The disease control rate was 20%, 28%, and 58% (Arms A, B, and C). The most frequent treatment-related adverse events (AEs) were hyperglycemia (54%) and diarrhea (39%) (Arm A); diarrhea (40%) and stomatitis (40%) (Arm B); fatigue (58%) and diarrhea (58%) (Arm C). The MTD was determined in all arms. Antitumor activity was observed with BI 860585 monotherapy and in combination with exemestane or paclitaxel. |
first_indexed | 2024-03-10T19:28:24Z |
format | Article |
id | doaj.art-192ed59c772e4e4f8e15c11087db92c9 |
institution | Directory Open Access Journal |
issn | 2072-6694 |
language | English |
last_indexed | 2024-03-10T19:28:24Z |
publishDate | 2020-05-01 |
publisher | MDPI AG |
record_format | Article |
series | Cancers |
spelling | doaj.art-192ed59c772e4e4f8e15c11087db92c92023-11-20T02:21:18ZengMDPI AGCancers2072-66942020-05-01126142510.3390/cancers12061425A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid TumorsFilippo de Braud0Jean-Pascal H. Machiels1Daniela Boggiani2Sylvie W.H. Rottey3Matteo Duca4Marie Laruelle5Stefania Salvagni6Silvia Damian7Lore D.F. Lapeire8Marcello Tiseo9Alexandre Dermine10Mahmoud Ould-Kaci11Juergen Braunger12Juliane Rascher13Daniela Fischer14Josef Hoefler15Gabriella L. Mariani16Sara Cresta17Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Oncology Department, University of Milan, via G. Venezian, 1, 20133 Milan, ItalyInstitut Roi Albert II, Service d’Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, BelgiumMedical Oncology Unit, University Hospital of Parma, Via Antonio Gramsci 14, 43126 Parma, ItalyDrug Research Unit Ghent, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, BelgiumMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, ItalyInstitut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, BelgiumPoliclinico S. Orsola Malphigi, via Giuseppe Massarenti, 13, 40138 Bologna, ItalyMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, ItalyDrug Research Unit Ghent, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, BelgiumMedical Oncology Unit, University Hospital of Parma, Via Antonio Gramsci 14, 43126 Parma, ItalyInstitut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, BelgiumBoehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT 06877, USABoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, GermanyBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, GermanyBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, GermanyStaburo GmbH, Aschauer Str. 26b, 81549 Munich, Germany, on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanyBoehringer Ingelheim, via Giovanni Lorenzini, 8, 20139 Milan, ItalyMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, ItalyThis phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with exemestane or paclitaxel in patients with advanced solid tumors. This 3+3 dose-escalation study assessed BI 860585 monotherapy (5–300 mg/day; Arm A), BI 860585 (40–220 mg/day; Arm B) with 25 mg/day exemestane, and BI 860585 (80–220 mg/day; Arm C) with 60–80 mg/m<sup>2</sup>/week paclitaxel, in 28-day cycles. Primary endpoints were the number of patients with dose-limiting toxicities (DLTs) in cycle 1 and the MTD. Forty-one, 25, and 24 patients were treated (Arms A, B, and C). DLTs were observed in four (rash (<i>n</i> = 2), elevated alanine aminotransferase/aspartate aminotransferase, diarrhea), four (rash (<i>n</i> = 3), stomatitis, and increased gamma-glutamyl transferase), and two (diarrhea, increased blood creatine phosphokinase) patients in cycle 1. The BI 860585 MTD was 220 mg/day (Arm A) and 160 mg/day (Arms B and C). Nine patients achieved an objective response (Arm B: Four partial responses (PRs); Arm C: Four PRs; one complete response). The disease control rate was 20%, 28%, and 58% (Arms A, B, and C). The most frequent treatment-related adverse events (AEs) were hyperglycemia (54%) and diarrhea (39%) (Arm A); diarrhea (40%) and stomatitis (40%) (Arm B); fatigue (58%) and diarrhea (58%) (Arm C). The MTD was determined in all arms. Antitumor activity was observed with BI 860585 monotherapy and in combination with exemestane or paclitaxel.https://www.mdpi.com/2072-6694/12/6/1425mTOR serine-threonine kinasesBI 860585clinical trialphase 1maximum tolerated dosepharmacokinetics |
spellingShingle | Filippo de Braud Jean-Pascal H. Machiels Daniela Boggiani Sylvie W.H. Rottey Matteo Duca Marie Laruelle Stefania Salvagni Silvia Damian Lore D.F. Lapeire Marcello Tiseo Alexandre Dermine Mahmoud Ould-Kaci Juergen Braunger Juliane Rascher Daniela Fischer Josef Hoefler Gabriella L. Mariani Sara Cresta A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors Cancers mTOR serine-threonine kinases BI 860585 clinical trial phase 1 maximum tolerated dose pharmacokinetics |
title | A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors |
title_full | A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors |
title_fullStr | A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors |
title_full_unstemmed | A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors |
title_short | A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors |
title_sort | phase 1 study of mtorc1 2 inhibitor bi 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors |
topic | mTOR serine-threonine kinases BI 860585 clinical trial phase 1 maximum tolerated dose pharmacokinetics |
url | https://www.mdpi.com/2072-6694/12/6/1425 |
work_keys_str_mv | AT filippodebraud aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT jeanpascalhmachiels aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT danielaboggiani aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT sylviewhrottey aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT matteoduca aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT marielaruelle aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT stefaniasalvagni aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT silviadamian aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT loredflapeire aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT marcellotiseo aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT alexandredermine aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT mahmoudouldkaci aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT juergenbraunger aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT julianerascher aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT danielafischer aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT josefhoefler aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT gabriellalmariani aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT saracresta aphase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT filippodebraud phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT jeanpascalhmachiels phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT danielaboggiani phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT sylviewhrottey phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT matteoduca phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT marielaruelle phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT stefaniasalvagni phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT silviadamian phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT loredflapeire phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT marcellotiseo phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT alexandredermine phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT mahmoudouldkaci phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT juergenbraunger phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT julianerascher phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT danielafischer phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT josefhoefler phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT gabriellalmariani phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors AT saracresta phase1studyofmtorc12inhibitorbi860585asasingleagentorwithexemestaneorpaclitaxelinpatientswithadvancedsolidtumors |